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Dementia with Lewy bodies (DLB) research has seen a significant growth in interna-
tional collaboration over the last three decades. However, researchers face a challenge
in identifying large and diverse samples capable of powering longitudinal studies and
clinical trials. The DLB research community has begun to focus efforts on supporting
the development and harmonization of consortia, while also continuing to forge net-
works within which data and findings can be shared. This article describes the current
state ofDLB research collaborations on each continent.Wediscuss several established
DLB cohorts, many of whom have adopted a common framework, and identify emerg-
ing collaborative initiatives that hold the potential to expand DLB networks and diver-
sify research cohorts. Our findings identify geographical areas into which the global
DLB networks should seek to expand, and we propose strategies, such as the cre-
ation of data-sharing platforms and the harmonization of protocols, whichmay further
potentiate international collaboration.
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1 BACKGROUND
Dementia with Lewy bodies (DLB) is characterized clinically by a
combination of core features, including fluctuating cognition, visual
hallucinations, spontaneous parkinsonism, and rapid eye movement
behavior disorder (RBD).1,2 Although the secondmost common formof
neurodegenerative dementia,3,4 DLB is under-researched (Figure 1),
under-recognized, frequently misdiagnosed, and undertreated.5,6
It is associated with a poor prognosis7 and limited therapeutic
options.8
Together, DLB and Parkinson’s disease dementia (PDD) comprise
the Lewy body dementias (LBD), a spectrum of disease with over-
lapping neurobiological mechanisms. Where PDD describes dementia
arising in the context of established idiopathicParkinson’s disease,DLB
refers to the onset of cognitive symptoms before, or within 1 year of,
the onset of parkinsonism.1
The research recommendations for DLB and other dementias as
part of the Alzheimer’s Disease-Related Dementias (ADRD) Summit
in 2019 specifically cited the establishment of consortia as an imper-
ative for advancing DLB research, highlighting the need for multicen-
ter collaboration in achieving adequately powered therapeutic trials.9
The ADRD Summit 2019 also advocated merging datasets, particu-
larly in studies using longitudinal and biomarker enriched designs, and
underlined the need for genetic and environmental diversity of these
research cohorts. Similarly, the fourth consensus report of the DLB
Consortium1 highlighted the potential of global harmonization in DLB
research, including common platforms for data and biomarker collec-
tion, and a consensus on outcomemeasures applied in clinical trials.
The Alzheimer’s Association International Society to Advance
Alzheimer’s Research and Treatment (ISTAART) LewyBodyDementias
Professional Interest Area (LBD PIA), founded in 2019, is focused on
advancing clinical care and research onDLB andPDD. To addressmany
of the unmet needs outlined above, the LBD PIA established three
working groups, focused on prodromal DLB, trial methods, and DLB
consortia.
2 AIMS AND METHODS
The LBD PIA ConsortiaWorking Group (CWG) aims to create a world-
wide network of DLB research groups. The first goal of the CWG has
been to describe the current state of global DLB research collabora-
tions, excluding other LBD such as PDD, for this specific endeavor. Dur-
ing the first CWGmeeting inOctober 2020, a writing groupwas estab-
lished (FD, JK, JBL, DA). Themain objectiveswere to detail factors spe-
cific to DLB that necessitate multi-site and multinational datasets and
identify existing national and international DLB research networks, as
well as explore strategies to enhance global collaboration.
The authors did not explore PDD consortia for this particular
endeavor, but did, over the course of the exercise, identify organi-
zations and research cohorts that have approached DLB and PDD
together under their collective termof LBD.Where necessary,we refer
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to LBD to remain consistent with these organizations but have taken
care to ensure that LBD andDLB have not been used interchangeably.
Thewriting groupused their pre-existingnetworks to identify active
DLB consortia, and invited representatives from each to participate as
named co-authors. All CWGmemberswere then invited to critique the
manuscript. The exercise focused onmulticenter consortia, comprising
groups frommore than one geographical area. It also aimed to identify
developing registries or networks that have emerged in geographical
areas in which active DLB consortia are not operating.
2.1 Why are DLB consortia needed?
Two central research themes are consistently identified as strategic
needs in developing DLB research:1,9 (1) clinical and biomarker char-
acterization of the longitudinal course of DLB, and (2) the creation of
trial-ready cohorts to facilitate publicly and privately sponsored clini-
cal trials. While DLB represents 10% to 20% of dementia cases,10 less
than one third of such cases are typically diagnosed in routine clinical
care.3 Adequately powered longitudinal or therapeutic DLB research
therefore necessitates specialized multi-site consortia, as this would
represent a logistic challenge for even larger research centers with
access to expert clinical opinion and diagnostic investigations.5 The
clinical heterogeneity of DLB, which can result in patients presenting
to a range of clinical settings, can also complicate recruitment, and can
contribute to the incorrect randomization of DLB patients to AD clini-
cal trials, and variable treatment response in DLB trials.
Important subanalyses, such as those exploring the lower rate
of core symptoms in women than in men with comparative DLB
pathology,11 and the role this might play in DLB’s clinical preponder-
ance inmen3 are also precluded by small sample sizes. Similarly, exami-
nation of the influence of geographical and ethnic factors on disease, as
has been observed in PD samples,12 has not yet been possible in DLB
cohorts.
Prodromal DLB studies represent an even greater challenge to
single-center designs. The recently publishedprodromalDLBcriteria13
have not yet been adopted within most clinical settings, complicating
case identification and recruitment. Studies investigating prodromal
DLB cohorts will require longer follow-up than those with DLB partici-
pants, and thus requiremore extensive resources.
Identifying opportunities to accumulate large sample sizes is par-
ticularly important in the nascent field of DLB genetic research. The
scale of this challenge, and the emerging capacity of the DLB commu-
nity to rise to it, is best exemplified in a recent genome-wide associ-
ation analysis in which five independent risk loci were identified. The
study included 2591 individuals with LBD and 4391 healthy controls,
recruited from 17 European and 27 North American sites.14 Genetic
studies also highlight the importance of increasing diversity of DLB
cohorts, wherein there has been an over-representation of European
and American populations.15 The role of other epigenetic features and
comorbidities further emphasizes the need for greater diversity, exem-
plified by the higher incidence of dementia in theAfricanAmerican and
CaribbeanHispanic ethnic groups in the United States.16
RESEARCH IN CONTEXT
1. Review: Through both pre-existing networks and the
membership of the LBD PIA, the authors identify active
multicenter DLB consortia. They also describe emerging
initiatives in countries without DLB consortia.
2. Interpretation: International collaboration among the
DLB community has increased significantly in recent
decades, and common characteristics of national and con-
tinental consortia demonstrate the potential to address
unmet scientific and strategic needs in the field.
3. Future directions: Expansion and diversification of DLB
networks are critical in supporting scientific progress.
Standardization of methodologies and practices, and the
development ofmechanisms to facilitate data sharing, are
important in maximizing the potential of DLB consortia.
HIGHLIGHTS! International collaborative research involving dementia
with Lewy bodies (DLB) has grown significantly in recent
decades.! The large sample sizes required for genetic studies, longi-
tudinal studies, and therapeutic trials in DLB support col-
laboration between international centers.! NewDLB initiatives and networks have emerged in recent
years, but further expansion and diversification are critical
in supporting scientific progress.! Strategies such as the creation of data-sharing platforms
and the harmonization of protocols would support further
collaboration.
Sharing laboratory resources and expertise could potentiate
research studies outside major research centers, particularly those
outside more economically developed countries, allowing analysis
of more diverse and globally representative groups. This is also sup-
ported through the standardization of validated protocols, such as
BIOMARKAPD17 and the recently established European Cluster for
Imaging Biomarkers (ECIB) guidelines (www.ebra.eu).
Finally, the benefits of collaboration extend beyond individual stud-
ies. There is an increasing number of funding initiatives aimed specif-
ically at multi-site and multinational efforts. The networks created by
collaboration will also provide researchers with larger platforms from
which to disseminate their work, and larger audiences with whom we
canengage andeducate, raising theprofile ofDLBglobally. This, in turn,
encourages more research funding, study participation, and collabora-
tion, further “widening the net” of our existing networks.
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F IGURE 1 Articles published on dementia with Lewy bodies, Alzheimer’s disease, and Parkinson’s disease between 2011 and 2020. Articles
(excluding review articles) were identified throughWeb of Science searches for “Alzheimer’s disease” (AD), “Parkinson’s disease” (PD), and
“Dementia with Lewy bodies” (DLB) onMarch 12, 2021
2.2 The international DLB consortium and
diagnostic criteria
International DLBnetworks have been pivotal to the conceptual evolu-
tion of the disease. Groups from Japan, the UK, and the United States
dominated DLB research prior to the first international consortium.18
Indeed, 21of the25authorswere from institutions in these three coun-
tries. By 1995, DLB was an emerging entity with 137 papers being
published that year. However, few of these reflected any collaboration
between international groups (Web of Science; Figure 2). Subsequent
DLB consortium meetings have seen the growth and diversification of
the DLB research community. Although researchers from Japan, the
UK, and the United States comprised 69% (31/45) and 79% (50/63)
of the authorship of the third19 and fourth1 consensus documents,
authors from 13 other countries were also represented.
Collaborative research both contributed to and arose from the
major conceptual developments brought forward by the third19
and fourth1 consensus criteria, such as the inclusion of dopamine
transporter single photon emission computed tomography (SPECT;
DaTscan) imaging, which paved the way for a phase III multicenter
study assessing its utility at 40 European sites.20 Work conducted by
the Mayo Clinic, USA, 21 and Barcelona, Spain, groups22 led to RBD’s
inclusion as a core feature in the fourth criteria, later supported by a
multicenter study involving24sites across11countries inNorthAmer-
ica, Europe, Asia, and Australia.23 The fourth consensus criteria also
included abnormal cardiac meta-iodobenzylguanidine (MIBG) uptake
as an indicative marker after the publication of encouraging data from
Japanese and Italian multicenter trials.24,25 The publication of crite-
ria for the diagnosis of prodromal DLB13 is further testament to the
development of international collaboration in recent years (Figures 1
and 2).26,27 The lack of established biomarkers for prodromal DLB,
however, highlights the need for a coordinated global effort in devel-
oping large prospective longitudinal cohorts from a wide range of geo-
graphical regions.
2.3 DLB consortia in Europe
The following sections highlight DLB consortia across the globe, begin-
ning with Europe. Although several European laboratories produce
research arising fromestablishedDLB cohorts, a full discussion of all of
these is beyond the scope of this paper; we have focused only on con-
sortia comprisingmultiple geographical sites (Table 1).
2.3.1 Italy
In 2016, the Italian Neurological Society for Dementia (SINdem) led
the creation of an Italian DLB study group that aimed to identify
established cohorts, develop standardized methods of data collection,
and optimize the diagnostic accuracy of DLB and prodromal DLB.
Six working groups were subsequently created to coordinate the
analysis of data collected from participating centers. These focused
on neuroimaging (magnetic resonance imaging [MRI], functional MRI
[fMRI], diffusion tensor imaging [DTI]), functional imaging, (DaTscan,
fluorodeoxyglucose positron emission tomography [FDG-PET],
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F IGURE 2 Multinational collaborations on dementia with Lewy bodies (DLB) publications (2000 and 2020). Each arc represents one of the 20
countries most frequently represented by authorship on amultinational paper published either in 2000 (n= 224; A) or 2020 (n= 470; B). Papers
identified through aWeb of Science search for “Dementia with Lewy bodies” on February 10, 2021. The size of each arc is proportionate to the
number of multinational papers published by institutions in respective countries. Connecting lines between arcs represent co-authorship between
researchers affiliated with institutions in different countries, and the width of each line corresponds to the number of multinational articles
co-authoredwith researchers from connected nations. Analysis was conducted using the bibliometrix package for R.28 AUS, Australia; AUT, Austria;
BEL, Belgium; CAN, Canada; CHE, Switzerland; CHN, China; DEU, Germany; DNK, Denmark; ESP, Spain; FIN, Finland; FRA, France; GBR, United
Kingdom; HUN, Hungary; IRL, Ireland; ISR, Israel; ITA, Italy; JPN, Japan; KOR, South Korea; NLD, Netherlands; NOR, Norway; QAT, Qatar; SWE,
Sweden; TUR, Turkey; USA, United States of America
amyloid-PET, SPECT-MIBG), neuroelectrophysiology (resting state
electroencephalography [rsEEG], visual evoked potentials, magne-
toencephalography), cerebrospinal fluid (CSF) biomarkers, neuropsy-
chological measures, and genetic analyses. The group also aimed to
develop sensitive and specific tools measuring longitudinal clinical
changes in DLB symptoms, and in 2018 commenced a project, funded
by the Italian Minister of Health, providing two-tiered recommenda-
tions for diagnostic and prognostic biomarker collection.
The Italian network is currently recruiting subjects with DLB, PDD,
andAlzheimer’s disease (AD) at its 133 participating dementia centers.
The first step of the initiative was to develop a semi-structured ques-
tionnaire among all participating centers, surveying the prevalence and
incidence of DLB; perspectives on clinical assessment; the relevance
and availability of diagnostic tools; pharmacological management of
cognitive, motor, and behavioral disturbances; and causes of hospital-
ization, with specific focus on delirium and its treatment. It also led the
way for the creation of a large longitudinal cohort, now available for
multicenter studies.28
2.3.2 United Kingdom (UK)
Building onUKDLB research, conducted particularly in Newcastle and
Cambridge, ENLIST-UK (“A Lewy body dementia network longitudi-
nal study in the UK’’), is a three-year observational longitudinal study
started in 2019, funded by Alzheimer’s Research UK and investigat-
ing predictors of cognitive decline in DLB. ENLIST-UK is coordinated
at King’s College London (KCL) with Cambridge, Exeter, Newcastle,
and University College London acting as participating sites. ENLIST-
UKaims to recruit subjectswithprobable, possible, andprodromalDLB
as well as AD and Parkinson’s disease (PD). Clinical and imaging data,
as well as CSF and blood, will be collected from each participant and
stored according to a standardized protocol.17 The ENLIST-UK study
will create a unified cohort of UKDLB patients with biological and lon-
gitudinal data.
2.3.3 European DLB consortium (www.e-dlb.com)
E-DLB was founded in 2015 from a grant awarded by the Euro-
pean Joint Programme–Neurodegenerative Disease (JPND) to stan-
dardize the design and methods for longitudinal prospective stud-
ies in DLB (https://www.neurodegenerationresearch.eu/wp-content/
uploads/2015/10/JPND-Report-Aarsland.pdf). Its primary aim is to
establish a repository for studies investigating the longitudinal devel-
opment of DLB using a standardized protocol. It currently involves
49 European centers from 20 countries, including those both the Ital-
ian SINdem and ENLIST-UK cohorts, each recruiting and following
patients with manifest and prodromal DLB. Thus, all patients prospec-
tively recruited in the Italian SINdem and ENLIST-UK are included
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in the prospective E-DLB cohort. Ten affiliated non-European centers
have also adopted the E-DLB protocol.
Standardized clinical assessments and biomarker collection in E-
DLB are guided by the JPND protocol. Three levels of complexity,
dependent on available resources, are specified, the lowest of which
describes procedures likely to be available at all specialized centers
seeing DLB patients.
Prior to the prospective cohort, for which recruitment is ongo-
ing, E-DLB created a retrospective database of more than 1200
DLB patients.29 Data from E-DLB have been analyzed by different
study groups, focusing on neuroimaging, neurophysiology, plasma and
CSF biomarkers, and genetics (https://www.e-dlb.com). Data can be
accessed via application to the E-DLB steering committee and mate-
rial transfer agreements are in place for this purpose. Biomarker hubs
providing infrastructure and logistical support for biomarker collection
and sample/data storage are also available.
Another central aim of E-DLB is to collaborate with international
networks, such as the Mayo Clinic DLB program.30 It has led to the
development of European subinitiatives such as the Nordic and Span-
ish DLB networks.
2.3.4 PDWAVES (www.pdwaves.eu)
The “PDWAVES” Consortium, established in 2014, comprises investi-
gators at 16 institutions in Italy, Switzerland, Austria, and Turkey. It
aims to advance the use of rsEEG “waves” in improving the under-
standing of neurophysiological mechanisms underlying the regulation
of brain arousal and vigilance in quiet wakefulness in patients with
DLB (n = 60), PD, or AD. PDWAVES also seeks to qualify the clinical
use of EEG biomarkers for diagnostic, prognostic, disease prediction,
monitoring, and therapy response purposes. Core activities include
the development of retrospective studies that include clinical, neu-
roimaging, and rsEEG data,31 as well as dissemination and outreach
activities.
2.4 DLB consortia in North America
Research centers in North America have contributed significantly to
the conceptual and scientific development of DLB and have laid the
foundations formany consortia discussed in this article.1,19 In the past,
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the North American DLB research community has benefitted from a
convergence of funding from governmental and advocacy organiza-
tions focused primarily on AD and PD.32,33
TheNationalAlzheimer’s ProjectAct (NAPA) established a “national
plan” aimed at the prevention and treatment of AD and, among
other dementias, DLB. Highlighting global collaboration through
the establishment of DLB consortia as a key strategy, NAPA has
opened up new funding streams for US researchers and their col-
laborators. For example, a recent expansion in the National Insti-
tute of Health’s dementia research program has permitted addi-
tional funding focused on DLB, including the establishment of the
US-based Dementia with Lewy Bodies Consortium (US-DLBC; see
below).
2.4.1 Alzheimer’s Disease Research Centers
(ADRCs)
The Alzheimer’s Dementia Care (ADC) program exemplifies how
US multicenter DLB datasets have arisen from AD projects. Cre-
ated by the National Institute on Aging (NIA), ADC initially aimed
to collect and maintain a “Minimum Data Set” (demographics, diag-
noses, and some neuropathological data) created through retrospec-
tive case note review and overseen by the National Alzheimer’s
Coordinating Center (NACC).32 The project has evolved to include
31 Alzheimer’s Disease Research Centers (ADRCs). Since 2005, the
ADC has been prospectively collecting longitudinal data using a stan-
dardized approach to the diagnosis and characterization of patients
with dementia; this “Uniform Data Set” (UDS) is now in its third
iteration.32
In 2017, an LBD module, an additional collection of scales, and
checklists aimed at better characterizing patients with LBD, was
added to the UDS. This included the Unified Parkinson’s Disease
Rating Scale (UPDRS) and Mayo Sleep Questionnaires among others
(https://naccdata.org/data-collection/forms-documentation/lbd-31).
The module allows the collection and standardization of neuroimaging
and polysomnography data from case note review. A 2018 analysis of
theUDS from theNACC reported that 824 patients had been assessed
with LBD (including PD), includingMRI (n= 114), CSF (n= 34), genetic
(n= 551), and neuropathological data (n= 353).32
The Mayo Clinic DLB program, a consortium of Mayo Clinic Facil-
ities in Minnesota and Florida, deserve specific discussion as ADRCs
contributing significantly to the DLB research landscape. Established
in 1991, the program has recruited large cohorts of patients with DLB
to several landmark studies.34,35 The sleep disorders clinic has proven
a rich resource for the identification and longitudinal assessment of
patients with idiopathic RBD.34 Mayo Clinics’ Longitudinal Imaging
Biomarkers of Disease Progression in DLB, established in June 2018,
aims to recruit 90 patientswithDLB, and 45 healthy controls, for longi-
tudinal assessment. Participantswill complete six visits over the 5-year
study. As well as annual FP-CIT, MRI, and lumbar puncture, they will
undergo amyloid PET and tau AV14-51 PET.
2.4.2 The North American Prodromal
Synucleinopathy (NAPS) Consortium
The North American Prodromal Synucleinopathy (NAPS) Consortium,
formed in 2018, has aimed to enroll 300 participants with RBD, but
without LBD, PD, or multisystem atrophy, anticipating one or more
future clinical trials of neuroprotective treatments to delay the onset
or prevent the overt synucleinopathies. The consortium is led byWash-
ington University in St. Louis, and comprises 10 centers (nine US,
one Canadian). Participants undergo a standardized assessment that
adopts the UDS structure, as well as blood sampling and optional
lumbar puncture. The consortium recently published preliminary neu-
ropsychological data from 70 participants.36 An extension of this
program—the NAPS2 Consortium—will begin in 2021 and continue
with annual visits for RBD participants over the subsequent 5 years.
2.4.3 Dementia with Lewy bodies Consortium
(US-DLBC)
In 2017, the National Institute of Neurological Diseases and
Stroke (NINDS) published requests for applications aimed toward
developing biomarkers for DLB and PDD as part of the Parkin-
son’s Disease Biomarkers Program (PDBP). One funded project
established a consortium of 10 sites across the US with exper-
tise in DLB (US-DLBC; https://pdbp.ninds.nih.gov/index.php/
Dementia-with-Lewy-Bodies-Consortium). The US-DLBC aims to
recruit a cohort of 216 subjects with DLB, PDD, and DLB-mild cog-
nitive impairment (MCI) across its 10 sites in the United States. Each
participant has a comprehensive clinical assessment at baseline, 6
months, and then annually for the duration of the study. CSF is col-
lected yearly inmost participants, using PDBP protocols. Furthermore,
Alzheimer’s Disease Neuroimaging Initiative-3 (ADNI-3)–compatible
MRI and DaTscan will be conducted at baseline and year two. A subset
of participants will consent to autopsy, and the study cohort has been
recruited with the secondary purpose of creating a sample available
for additional therapeutic studies. Clinical data are entered into
the PDBP (https://pdbp.ninds.nih.gov/data-management-resource)
and clinical and neuropathologic data into the NACC database
(https://naccdata.org).
To date, the US-DLBC has recruited 122 DLB or MCI-DLB partici-
pants, themajority with data available on imaging (MRI, DaTscan), clin-
ical characterization, and biosamples, including CSF and blood prod-
ucts. A large proportion of participants (> 80%) have consented to post
mortem brain donation.
2.4.4 Research Centers of Excellence
The Lewy Body Dementia Association (LBDA), the largest and most
active DLB charity, developed a Research Centers of Excellence pro-
gram in2017,which comprises expert clinicians and researchers across
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26US centerswith twoprimary goals: (1) to increase the quality of clin-
ical care for patients with LBD and (2) to accelerate research in thera-
peutics for LBD.37 Similar to the LBD PIA, several working groups are
focused on specific topics pertaining to LBD. In 2019, the LBDA also
started the Industry Advisory Council (IAC) to provide a collaborative
forum for discussion among LBD experts, pharmaceutical industries,
governmental agencies, and the nonprofit LBDA to address challenges
and opportunities for LBD clinical trials.37
2.5 Canada
The Canadian DLB initiative is a team within a larger consortium,
the Canadian Consortium on Neurodegeneration in Aging (CCNA;
www.ccna-ccnv.ca). Established in 2014, theCCNA is currently recruit-
ing cognitively intact older adults and people with neurodegenerative
disorders across the country.38 Participants undergo a standardized
imaging, clinical, and neuropsychological protocol that also includes
biofluid collection and optional lumbar puncture. Follow-up is sup-
ported at 1 and 2 years, and participants have the option to volunteer
for brain donation. With more than 1100 enrolled to date, the Lewy
body cohort includes 30 with DLB, and 17 with PDD. It is hoped
that this cohort will grow to a target of 200 people with LBD. The
consortium aims to identify diagnostic and prognostic biomarkers
across the Lewy body spectrum.
2.6 DLB consortia in Australia
The ForeFront DLB initiative, based in Sydney, has been active since
2017. It recruits patients for longitudinal assessment with estab-
lished DLB, as well as PD, PDD, MCI, idiopathic RBD, and other pro-
dromal DLB subgroups. A sample of these participants has under-
gone detailed baseline motor, neuropsychiatric, sleep, MRI, chrono-
biology, genetic, clinical chemistry, and gait measure assessments.
Clinical data from probable DLB cases using the Fourth consen-
sus diagnostic criteria1 has been published, which demonstrated a
clustering of the specific core and supportive DLB features as well
as proposing a novel DLB-Parkinsonism scale to help standardize
diagnosis.39 Another Australian initiative, The Lewy Body Study, is
based in Melbourne with collaborators in Perth. It represents a
prospective observational longitudinal study focused on the impact of
proteinopathies and vascular impairments on disease trajectories in
patients with LBD. Participants undergo standardized clinical assess-
ments as well as MRI, PET, and blood biomarkers with optional CSF
collection.
2.7 DLB consortia in Latin America
Several multicenter dementia initiatives have been established across
Latin America (Table 1). The Brazilian Biobank for Aging Studies at Uni-
versity of São Paolo, led by Lea Grinberg and colleagues, has collected
more than 1300 brains since 2004 from patients with neurodegener-
ative diseases, including DLB and PD. Supported by multiple local and
international stakeholders, the Biobank has produced multiple publi-
cations, and contributes DLB prevalence data to a national population-
based cohort. The Federal University of São Paulo has produced sev-
eral single-center studies assessing predictors of dementia, language
impairments, or differential diagnoses between LBD and AD.40 Ongo-
ing projects include the comparison of CSF and serum markers in DLB
and AD.
The Colombian Consortium for the Study of Dementia with Lewy
Bodies (COL-DLB), a multicenter longitudinal study led by groups in
Bogotá, Medellín, and Cali, was created in 2019. COL-DLB aims to cre-
ate a registry of patients with DLB with clinical, neuroimaging (MRI,
FDG-PET, DaTscan), CSF and blood biomarkers (p-tau, neurofilament
light chain, and neurogranin), and EEG data collected in accordance
with the E-DLB protocol.41
The Peruvian Institute of Neurosciences has recruited various
cohorts of patients with PD and DLB since 2013. These have mainly
focused on clinical and neuropsychological data. Efforts are underway
to harmonize the protocol to that of E-DLB.
The consortium to expand dementia research in Latin America
(ReDLat) is a multinational initiative supported by NIH-NIA, the
Alzheimer’s Association, the Rainwater Charitable Foundation (Tau
Consortium), the Global Brain Health Institute, and Takeda Phar-
maceutical Company. It aims to recruit participants with AD, fron-
totemporal dementia (FTD), and now also DLB, and controls from
10 sites in Argentina, Brazil, Chile, Colombia, Mexico, Peru, and the
United States. By combining standardized genetic (whole genome)
data, multimodal neuroimaging, behavioral (cognitive and socioeco-
nomic/sociodemographic determinants of health), and EEG (in a sub-
sample) measures and machine learning, ReDLat will compare the
genetic and sociodemographic risk factors for AD and FTD in Latin
American countries to those inUSpopulations. EveryDLBpatient iden-
tified during ReDLat recruitment will undergo complete assessment
using the study protocol. The program aims to amass more than 4200
patients, of whom an estimated 5% to 10% will have DLB, across Latin
America by 2025.42,43
2.8 DLB consortia in Asia
2.8.1 Japan
The DLB Society Japan (DLBSJ) was established by Dr. Kenji Kosaka in
2007 and has more than 400members. It is funded by a grant from the
Japan Foundation for Neuroscience and Mental Health. The DLBSJ’s
primary purpose is to stimulate basic and clinical research on DLB and
to increase public awareness in finding better management options.
Core members and their multicenter networks have contributed sig-
nificantly to the advancement of diagnostic techniques. In particular,
DLBSJ have led research on the use ofMIBGmyocardial scintigraphy25
and standardized methods for its use in discriminating probable DLB
and probable AD.
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Japanese groups have an impressive track record in planning and
completing several clinical trials in DLB. Multicenter phase 3 random-
ized controlled trials of donepezil for cognition (n = 142)44 and zon-
isamide for parkinsonism (n = 346)45 have led to both agents being
approved by the Japanese government for use in DLB.
2.8.2 India
Dementia diagnosis in India has previously been limited by the lack of
standardization of assessments in movement disorders and cognitive
neurology, but in recent years progress has been made toward rec-
tifying this. The Parkinson’s Research Alliance of India (PRAI) move-
ment disorders group has developed nationwide research, including a
recently formed Indian DLB consortium. PRAI coordinates the collec-
tion and annual follow-up of a registry of patients with DLB and PDD
across India. Standardized evaluation will follow the E-DLB protocol,
with one of two levels of detail of data collection (minimal and detailed)
chosen by participating centers. The assessment includes the Indian
Council of Medical Research neurocognitive toolbox (ICMR-NCTB), a
recent endeavor to standardize cognitive assessment scales for Indian
populations.46 It is available in five languages, and it includes cultural
adaptations in existing scales. Cognitive tests for the illiterate popula-
tion have been implemented when possible, and new tests added by a
group of multidisciplinary experts from across India.
2.8.3 China
Several multicenter DLB registries have been developed in China with
the support of an established national dementia research infrastruc-
ture (Table 1). The PekingUniversity Dementia Collaborative Research
Network (PKU-DCRN), comprising 30 participating hospitals, main-
tain a DLB registry comprising 220 cases. The organization has also
recently begun a community-based DLB screening program, in which
older adults with RBD, visual hallucinations, or parkinsonism are
invited to undergo comprehensive cognitive assessment, MRI, and
DaTscan. The China Dementia with Lewy Bodies Collaboration Center
(CDCC) registry, based at TianjinDementia Institute, has recruited 512
DLB cases.
The Innovation Center for Neurological Disorders in Xuanwu
Hospital, Capital Medical University (CMU-ICND), has established
a database of 50 patients with DLB, and Zhejiang University has
recruited 50 DLB cases with planned neuropathological follow-up at
China’s National Brain Bank. These registries collect cognitive, neu-
ropsychiatric data; multi-modalityMRI imaging; and in some instances,
EEG, polysomnography, and DaTscan data. Blood and CSF samples are
retrieved from a small proportion of participants.
Plans are in development to harmonize these registries with each
other, and with other international consortia. It is also hoped that har-
monization will allow identification of a large trial-ready cohort suit-
able for studies investigating early diagnosis and intervention. One
such trial investigating the efficacy and safety of sodium oligomannate
(GV-971) for cognitive impairment in DLB is scheduled to begin in the
next year.
3 DISCUSSION
Wehave presented thework and future directions ofDLB research ini-
tiatives fromaround theworld (Tables 1 and2). The growth anddiversi-
fication of the global DLB community are evidenced by the authorship
of diagnostic criteria, as well as by the volume of multicenter papers
published per year (Figures 1 and 2). Regular communication is criti-
cal in sustaining this growth and ensures that consensus can continue
to form around the growing evidence base. The feasibility of more fre-
quent international DLB meetings should therefore be explored along
with greater use of online platforms.
The ISTAART LBDPIA group has helped establish regular communi-
cation among members of the LBD community, filling the gap between
international DLB consortia meetings. The publication of this article
and the inclusion of a dedicated Featured Research session at the
Alzheimer’s Association International Conference 2020 demonstrate
the advantages that have already arisen from the group. Virtual meet-
ings have widened access beyond the groups that have traditionally
dominated the field. While recognizing potential biologic underpin-
nings to risk for LBD in different cohorts, consideration should be paid
to how the democratization of the community can be extended, par-
ticularly in supporting the participation of women, people of color, and
researchers from low-income countries in the DLB community.
Established consortia in Europe and theUnited States have recently
been joined by continental initiatives in Australia and Latin America.
Emerging Chinese and Indian networks hold enormous potential in
accessing large populations capable of diversifying global DLB sub-
jects. However, the absence of initiatives in Africa and theMiddle East
highlight that DLB cohorts are not yet reflective of a global popula-
tion, and identify these regions as the next frontiers in DLB research.
A strategic goal among international DLB organizations should be
determining how best to support research and practice in these areas,
such as clearer, more established mechanisms for accessing men-
torship. The authors would welcome requests for advice or support
from anyone considering establishing a DLB cohort in their respective
center.
A further consideration in the development of consortia is the
standardization of methodologies and practices. Research consortia,
such as the ADNI47 and Parkinson’s Progression Markers Initiative
(PPMI)48 have achieved success both in both creating large datasets
and in nurturing a global infrastructure that theDLBcommunity should
aim to replicate. Currently, this is challenged by a lack of information
sharing; only a handful of the consortia discussed in this article have
published protocols in peer-reviewed journals. A single, open access,
curated resource of active DLB consortia, or a bespoke journal for DLB
research, could help rectify this. As novel methodologies emerge, such
as the use of electronic health-care records to enrich research cohorts
with naturalistic clinical data, DLB-specific platforms will be critical
in supporting early standardization of these techniques. Inclusion of
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TABLE 2 Selected recent publications, and planned future directions, of DLB research groups in each region
Selected recent publications (Authors, Title, Journal, Year) Future directions
EUROPE
Abdelnour et al. The combined effect of amyloid beta and tau biomarkers on brain
atrophy in dementia with Lewy bodies.Neuroimage Clin. 202050.
! Longitudinal characterization of DLB, including
prodromal disease! Develop common platforms for data sharing! Promote further collaboration between national
and international consortia
Oppedal et al. A signature pattern of cortical atrophy in dementia with Lewy
bodies: A study on 333 patients from the EuropeanDLB consortium. Alzheimer’s
Dement. 201951.
Roberts et al. Accuracy of cardiac innervation scintigraphy for mild cognitive
impairment with Lewy bodies.Neurology. 202152.
van der Zande et al. Diagnostic and prognostic value of EEG in prodromal dementia
with Lewy bodies.Neurology. 202053.
NORTHAMERICA
Chen et al. beta-Amyloid PET and (123)I-FP-CIT SPECT inmild cognitive
impairment at risk for Lewy body dementia.Neurology. 202154.
! Develop novel DLB biomarkers! Develop novel therapeutic strategies! Develop infrastructure and networks capable of
recruiting large trial-ready cohorts
Fields et al. The North American Prodromal Synucleinopathy (NAPS) Consortium:
Baseline neuropsychological findings in 136 participants.Alzheimer’s Dement.
202036.
Naasan et al. Psychosis in neurodegenerative disease: differential patterns of
hallucination and delusion symptoms. Brain. 202155.
Chia et al. Genome sequencing analysis identifies new loci associatedwith Lewy
body dementia and provides insights into its genetic architecture.Nat Genet.
202114.
SOUTHAMERICA
BordaMG et al. Colombian consortium for the study of Lewy body dementia
COL-DLB. J Neurol Sci. 202041.
! Expand existing DLB consortia (i.e., Colombian
consortium) to include other regional dementia
initiatives! Investigate specific genetic and environmental risk
factors for DLB in Latin America! Enhance capacity for clinical trials! Promote networking and translational research
deOliveira FF, et al. Neuropsychiatric feature profiles of patients with Lewy body
dementia. Clin Neurol Neurosurg. 202040.
Ibanez et al. The Latin America and the Caribbean Consortium onDementia
(LAC-CD): FromNetworking to Research to Implementation Science. J
Alzheimers Dis. 202142.
ASIA
Gan et al. Clinical characteristics of Lewy body dementia in Chinesememory clinics.
BMCNeurol. 202156.
! Harmonize existing DLB registries! Recruit large trial-ready cohorts! Further develop registries in India and South Asia
Murata et al. Effect of zonisamide on parkinsonism in patients with dementia with
Lewy bodies: A phase 3 randomized clinical trial. Parkinsonism Relat Disord.
202045.
Iyer GK, et al. Standardising dementia diagnosis across linguistic and educational
diversity: Study design of the Indian Council ofMedical
Research-Neurocognitive Tool Box (ICMR-NCTB). J Int Neuropsychol Soc. 202046.
(Continues)
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TABLE 2 (Continued)
Selected recent publications (Authors, Title, Journal, Year) Future directions
AUSTRALIA
Matar et al. Clinical features of Lewy body dementia: insights into diagnosis and
pathophysiology. J Neurol. 202039.
! Investigate disease trajectories! Investigate the neurobiology underpinning
cognitive fluctuations! Develop testing paradigms for core features
Matar et al. Cognitive fluctuations in Lewy body dementia: towards a
pathophysiological framework. Brain. 202057.
Phillips et al. Evaluating the sustained attention response task to quantify cognitive
fluctuations in dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 202058.
Abbreviation: DLB, dementia with Lewy bodies.
standardized operating procedures for the collection and analysis
of EEG and neuroimaging data, and the adoption of data-sharing
systems like theHiveDB,49 could also allow groups to benefit from the
community’s shared expertise.
Amore extensive and cohesive DLB research community could help
support the development of single, recognizable points of contact with
which engagement with pharmaceutical and biotechnology industries,
regulatory industries, and political entities, could be facilitated. Global
collaboration in these areas could assist the development of new ther-
apeutic approaches by increasing the availability and size of trial-ready
cohorts as well as helping to share the expertise of groups such as
DLBSJ, who have successfully workedwith industry.
Involvement of patients and caregivers is crucial in guiding and sup-
porting research. The US LBD Association and UK Lewy Body Soci-
ety perform excellent work in their respective jurisdictions, and a new
LewyBody Ireland society is beingestablished, but the creationof a sin-
gle global charity could provide further funding opportunities, pooling
of resources, and opportunities to engage the global public in raising
awareness of DLB.
4 CONCLUSIONS
The development of global research networks should assist in address-
ing currently unmet needs in DLB research, facilitating better diag-
nostic definition, harmonization of protocols, and larger sample sizes.
As national and continental consortia continue to grow, an important
focus of these networks will be to ensure that levels of development
at each are complementary, rather than competing. Participation of
respective consortia in standardization of trial methodology, a key aim
of the ISTAART LBD PIA, would support the development of a global
DLB cohort with clinical, genetic, and biomarker characterization, as
well as potentiate the work of individual groups.
Creation of common data-sharing platforms, and curated reposito-
ries of resources, could enable more detailed and powerful analyses
of existing cohorts and advance the understanding of clinical symp-
toms and prognosis. This infrastructure would facilitate the creation of
a global DLB registry, and provide opportunities to develop new, more
effective treatments through identification of trial-ready DLB cohorts.
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